Reported 2 days ago
Fulgent Genetics experienced a remarkable stock surge of over 8% on Friday, despite a generally down market, following the announcement of its unexpected profit and strong revenue growth for the second quarter. The company reported revenues approaching $82 million, a year-over-year increase of over 15%, although adjusted net income fell by 56%. Analysts had projected a loss, making the actual results a pleasant surprise for investors, who also welcomed an upward revision in revenue and loss guidance for the full year.
Source: YAHOO